GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Integrum AB (OSTO:INTEG B) » Definitions » EV-to-EBITDA

Integrum AB (OSTO:INTEG B) EV-to-EBITDA : -10.99 (As of Jun. 28, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Integrum AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Integrum AB's enterprise value is kr390.23 Mil. Integrum AB's EBITDA for the trailing twelve months (TTM) ended in Apr. 2025 was kr-35.49 Mil. Therefore, Integrum AB's EV-to-EBITDA for today is -10.99.

The historical rank and industry rank for Integrum AB's EV-to-EBITDA or its related term are showing as below:

OSTO:INTEG B' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1633.99   Med: -9.54   Max: 11845.45
Current: -10.99

During the past 11 years, the highest EV-to-EBITDA of Integrum AB was 11845.45. The lowest was -1633.99. And the median was -9.54.

OSTO:INTEG B's EV-to-EBITDA is ranked worse than
100% of 496 companies
in the Medical Devices & Instruments industry
Industry Median: 15.47 vs OSTO:INTEG B: -10.99

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-06-28), Integrum AB's stock price is kr19.92. Integrum AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2025 was kr-1.570. Therefore, Integrum AB's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Integrum AB EV-to-EBITDA Historical Data

The historical data trend for Integrum AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integrum AB EV-to-EBITDA Chart

Integrum AB Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,120.43 276.90 -22.00 123.34 -7.23

Integrum AB Quarterly Data
Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 123.34 1,166.44 -29.25 -17.20 -7.23

Competitive Comparison of Integrum AB's EV-to-EBITDA

For the Medical Devices subindustry, Integrum AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integrum AB's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Integrum AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Integrum AB's EV-to-EBITDA falls into.


;
;

Integrum AB EV-to-EBITDA Calculation

Integrum AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=390.225/-35.493
=-10.99

Integrum AB's current Enterprise Value is kr390.23 Mil.
Integrum AB's EBITDA for the trailing twelve months (TTM) ended in Apr. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-35.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Integrum AB  (OSTO:INTEG B) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Integrum AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=19.92/-1.570
=At Loss

Integrum AB's share price for today is kr19.92.
Integrum AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-1.570.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Integrum AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Integrum AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Integrum AB Business Description

Traded in Other Exchanges
Address
Krokslatts Fabriker 50, Molndal, SWE, SE-431 37
Integrum AB provides the system for bone-anchored prostheses that improves the lives of people with amputations. Its solutions include OPRA implant system, Neural prosthetics, Phantom limb pain treatment, and Prosthetic components. The company is also engaged in developing technology for mind-controlled prostheses and treatment for phantom limb pain.

Integrum AB Headlines

No Headlines